A Phase 3, Placebo-Controlled, Randomized, Double-blind, Parallel-arm Trial to Assess the Safety and Efficacy of MAT9001 in Subjects With Severe Hypertriglyceridemia: The AMPLIFY Trial

NCT04662528 Phase 3 WITHDRAWN

To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and \< 2000 mg/dL.

Details

Lead sponsor	Matinas Biopharma, Inc
Phase	Phase 3
Status	WITHDRAWN
Start date	2021-06
Completion	2022-10

Conditions

• Severe Hypertriglyceridemia

Interventions

• Placebo
• MAT9001 (omega-3 pentaenoic acid)

Primary outcomes

• The percent change from baseline to end of study for MAT9001 versus Placebo — 12 weeks
  Difference between MAT9001 and placebo treatment groups in triglyceride lowering effect